Company Overview and News

20
AMDA / Amedica Corporation null

2018-06-12 sec.gov
Amedica Corporation 1885 West 2100 South
AMDA

44
AMDA / Amedica Corporation null (Prospectus)

2018-05-11 sec.gov
Filed Pursuant to Rule 424(b)(4) Registration No. 333-223032 Amedica Cor
AMDA

19
BRIEF-Amedica Corp Announces Pricing Of $15 Mln Public Offering Of Units

2018-05-10 reuters
* AMEDICA CORPORATION ANNOUNCES PRICING OF $15,000,000 PUBLIC OFFERING OF UNITS CONSISTING OF CONVERTIBLE PREFERRED STOCK AND WARRANTS
AMDA

19
Amedica Corporation Announces Pricing of $15,000,000 Public Offering of Units Consisting of Convertible Preferred Stock and Warrants

2018-05-10 globenewswire
SALT LAKE CITY, May 10, 2018 (GLOBE NEWSWIRE) -- Amedica Corporation (NASDAQ: AMDA) an innovative biomaterial company that develops and commercializes silicon nitride for biomedical applications, today announced the pricing of an underwritten public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15,000,000, which excludes underwriting discounts and commissions and offering expenses payable by Amedica.
AMDA

33
AMDA / Amedica Corporation null

2018-05-10 sec.gov
As filed with the Securities and Exchange Commission on May 10, 2018 Registration No. 333-______
AMDA

39
AMDA / Amedica Corporation null

2018-05-10 sec.gov
As filed with the Securities and Exchange Commission on May 10 , 2018 Registration No. 333-223032
AMDA

40
AMDA / Amedica Corporation null

2018-05-09 sec.gov
As filed with the Securities and Exchange Commission on May 9 , 2018 Registration No. 333-223032
AMDA

23
Amedica Corporation Provides Update on its Clinical Studies

2018-05-08 globenewswire
SALT LAKE CITY, May 08, 2018 (GLOBE NEWSWIRE) -- Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company that develops and commercializes silicon nitride for biomedical applications, today provided an update on its clinical study activities.
AMDA

AMDA : Amedica Corporation Stock Analysis and Research Report

2017-11-10 - Asif

Amedica Corporation is a materials company focused on developing, manufacturing and selling silicon nitride ceramics that are used in medical implants and in a variety of industrial devices. At present, the company commercialize silicon nitride in the spine implant market. The company believe that its silicon nitride manufacturing expertise positions it favorably to introduce new and innovative devices in the medical and non- medical fields. The company also believe that Amedica is the first and only company to commercialize silicon nitride medical implants. Amedica has received 510(k) regulatory clearance in the United States, a CE mark in Europe, and ANVISA approval in Brazil for a number of its devices that are designed for spinal fusion surgery. To date, more than 28,000 of its silicon nitride devices have been implanted into patients, with an 8-year successful track record. The company intend to file an FDA 510(k) submission for clearance in the United States of a novel compos...

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to AMDA / Amedica Corporation on message board site Silicon Investor.

Amdahl
CUSIP: 023435100